Scarica l'app Stockscreener
55.59
2.77%
1.50
Dopo l'orario di chiusura:
56.25
0.66
+1.19%
Precedente Chiudi:
$54.09
Aprire:
$54.61
Volume 24 ore:
1.95M
Relative Volume:
0.79
Capitalizzazione di mercato:
$10.69B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
20.67
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
+0.29%
1M Prestazione:
-9.52%
6M Prestazione:
+5.64%
1 anno Prestazione:
-22.28%
Intervallo 1D:
$54.61
$55.73
Intervallo di 1 settimana:
$53.35
$55.89
Portata 52W:
$50.76
$73.18
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
55.59 | 10.40B | 2.95B | 523.88M | 620.18M | 2.69 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-20 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Downgrade | Stifel | Buy → Hold |
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo! Finance Canada
Assenagon Asset Management S.A. Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Swiss Life Asset Management Ltd Sells 54,282 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
BioMarin Pharmaceutical (BMRN) reports positive results from ongoing trials of VOXZOGO - MSN
Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
BioMarin (BMRN) legal chief has 1,273 shares withheld for taxes - Stock Titan
BioMarin (BMRN) CTO reports 1,693-share tax withholding, holds 84,140 - Stock Titan
BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax - Stock Titan
BioMarin (BMRN) CEO reports tax-withholding share disposition - Stock Titan
Hudson Bay Capital Management LP Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin (BMRN) EVP Hubbard receives stock awards and withholds shares for tax - Stock Titan
BioMarin (NASDAQ: BMRN) EVP granted stock, options and covers tax with shares - Stock Titan
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease - TipRanks
BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN
Form 4 Biomarin Pharmaceutical Inc For: 17 March By Investing.com - Investing.com South Africa
BioMarin (BMRN) legal chief receives options, RSUs and tax withholding - Stock Titan
BioMarin (NASDAQ: BMRN) CFO gets stock grants and tax share withholding - Stock Titan
BioMarin (BMRN) CEO granted 89,200 options and 62,440 RSUs in 2026 awards - Stock Titan
Price-Driven Insight from (BMRN) for Rule-Based Strategy - Stock Traders Daily
A Look At BioMarin Pharmaceutical (BMRN) Valuation After A Year Of Softer Share Price Momentum - Sahm
Wolfe Research Maintains Outperform on BioMarin (BMRN) March 16, 2026 - Meyka
BioMarin Pharmaceutical Inc. 8-K Filing: Company Information, Address, and Stock Details (March 16, 2026) - Minichart
Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap DownTime to Sell? - MarketBeat
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
Wolfe Research reiterates Outperform on BioMarin stock at $95 By Investing.com - Investing.com India
Wolfe Research reiterates Outperform on BioMarin stock at $95 - Investing.com
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace
BioMarin stops mid-stage trials of bone disorder treatment - Reuters
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials - TipRanks
BioMarin shares drop 4% as Voxzogo trials are discontinued (BMRN:NASDAQ) - Seeking Alpha
BioMarin (NASDAQ: BMRN) stops VOXZOGO trials in Turner, SHOX and ACAN - Stock Titan
Biomarin Pharmaceutical Inc Announces Discontinuation of Dosing and Enrollment in Phase 2 Trials for Voxzogo in Turner Syndrome, Shox-Deficiency and Aggrecan-Deficiency - marketscreener.com
BioMarin Pharmaceutical Stock (ISIN: US09061G1013) Gains Momentum on Voxzogo Data and $4.7B Amicus A - AD HOC NEWS
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case - ChartMill
BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com Nigeria
BMRN SEC FilingsBiomarin Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Braidwell LP Acquires Shares of 528,000 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Boone Capital Management LLC Sells 118,903 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Prolonged Share Price Weakness - simplywall.st
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia - Sahm
BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN
BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents - Yahoo Finance
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):